Why Pfizer Chose Data Over Drugs in Its Adaptive Deal

Adaptive Biotechnologies’ newly announced agreements with Pfizer, which carry potential milestone payments of up to $890 million, stand out for how they are structured.

The deals are non-exclusive, focused on early discovery and data access, and stop short of committing either company to a specific therapeutic asset or development timeline. According to Pfizer and Adaptive, the agreements center on T-cell receptor discovery in rheumatoid arthritis and on licensing access to Adaptive’s proprietary immune-receptor datasets for broader research use.

Under the first agreement, Adaptive will apply its immune medicine platform to analyze Pfizer-provided clinical samples from rheumatoid arthritis patients, with the goal of identifying disease-associated T-cell receptors. Pfizer will retain responsibility for downstream development and commercialization of any resulting therapies. Under the second agreement, Pfizer licensed access to portions of Adaptive’s large TCR-antigen binding dataset, which Pfizer said it plans to use to train internal AI and machine-learning models across multiple disease areas. Adaptive will receive upfront payments and may earn additional milestone and licensing fees, though specific financial terms beyond the $890 million potential were not disclosed.

Adaptive chief executive Chad Robins said the company has “amassed a treasure trove of immune receptor data along with an enhanced understanding of T-cell biology,” adding that the dataset “has the potential to inform discoveries across immunology programs that may lead to next-generation therapeutics in RA.”